BioLineRx Ltd.
A clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases.
BLRX | TA
Overview
Corporate Details
- ISIN(s):
- US09071M2052 (+1 more)
- LEI:
- 529900AKIOSC15Y63R18
- Country:
- Israel
- Address:
- Modi'in Technology Park, 2 HaMa'ayan Street, 7177871 Modi'in
- Website:
- https://www.biolinerx.com/
- Sector:
- Manufacturing
Description
BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-03-12 13:56 |
BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update
|
English | 38.1 KB | ||
| 2020-03-05 17:56 |
6K: BioLineRx reports results of extraordinary meeting of shareholders
|
English | 129.4 KB | ||
| 2020-03-05 17:56 |
6K: BioLineRx reports results of extraordinary meeting of shareholders
|
English | 38.0 KB | ||
| 2020-02-27 14:56 |
Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in C…
|
English | 146.5 KB | ||
| 2020-02-27 14:56 |
Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in C…
|
English | 38.1 KB | ||
| 2020-02-16 10:45 |
Form 13G filed with the SEC by BVF group
|
English | 162.8 KB | ||
| 2020-02-16 10:45 |
Form 13G filed with the SEC by BVF group
|
English | 37.8 KB | ||
| 2020-02-10 12:58 |
Form 13G/A filed with the SEC by Senvest Management
|
English | 123.0 KB | ||
| 2020-02-10 12:58 |
Form 13G/A filed with the SEC by Senvest Management
|
English | 37.8 KB | ||
| 2020-01-30 14:57 |
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
ON MARCH 5, 20
|
English | 130.7 KB | ||
| 2020-01-30 14:57 |
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
ON MARCH 5, 20
|
English | 155.9 KB | ||
| 2020-01-30 14:57 |
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
ON MARCH 5, 20
|
English | 61.2 KB | ||
| 2020-01-22 14:58 |
BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202…
|
English | 80.8 KB | ||
| 2020-01-22 14:58 |
BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202…
|
English | 38.2 KB | ||
| 2020-01-14 14:58 |
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the …
|
English | 81.0 KB |
Automate Your Workflow. Get a real-time feed of all BioLineRx Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioLineRx Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioLineRx Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
